Azelaprag

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Azelaprag (original Amgen development code AMG 986, subsequently licensed to BioAge Labs and renamed BGE-105) is a drug which is a selective, small-molecule agonist for the apelin receptor. It was originally developed as a potential treatment for heart failure and has subsequently been investigated for other applications such as obesity and muscle wasting in elderly or bed-bound patients.

Azelaprag (original Amgen development code AMG 986, subsequently licensed to BioAge Labs and renamed BGE-105) is a drug which is a selective, small-molecule agonist for the apelin receptor. It was originally developed as a potential treatment for heart failure and has subsequently been investigated for other applications such as obesity and muscle wasting in elderly or bed-bound patients.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370557281 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.